Plasmodium heme polymerization process

The Plasmodium heme polymerization process is a critical detoxification pathway utilized by malaria parasites, such as Plasmodium falciparum, during their intraerythrocytic stage (Sullivan, 2002). As the parasite consumes host hemoglobin within its acidic digestive vacuole to obtain amino acids, it releases free heme (ferriprotoporphyrin IX), which is highly toxic due to its ability to generate reactive oxygen species and disrupt lipid membranes (Egan, 2008). To survive, the parasite converts this toxic heme into an insoluble, chemically inert crystalline polymer called hemozoin, or "malaria pigment" (Coronado et al., 2014). This biocrystallization process is the primary pharmacological target for several classes of antimalarial drugs, most notably the 4-aminoquinolines like chloroquine and amodiaquine. These drugs interfere with the polymerization by binding to the heme dimers or the growing crystal surface, resulting in the accumulation of toxic free heme that ultimately kills the parasite (Egan, 2008). Despite its historical success as a target, the emergence of resistance—primarily through mutations in the Plasmodium falciparum chloroquine resistance transporter (PfCRT)—remains a significant therapeutic challenge (Fidock et al., 2000).

Other names

Hemozoin formationHeme detoxificationβ-hematin crystallizationHeme biocrystallizationHeme sequestrationβ-hematin formation

Inhibition of heme polymerization into hemozoin, leading to the accumulation of toxic free ferriprotoporphyrin IX which causes parasite cell death via membrane damage and oxidative stress (Egan, 2008; Coronado et al., 2014).